| 摘要 |
The present invention relates to selective anxiolytic therapeutic agents which allow for the treatment of anxiety-related disorders with less severe side-effects, such as sedative and amnesic effects, and in particular, dependence liability. These selective agents selectively or preferentially bind the a2-GABAA receptor, as compared to the alpha1-GABAA receptor. Alternatively, these selective agents selectively or preferentially activate the alpha2-GABAA receptor, as compared to the alpha1-GABAA receptor. The present invention also relates to methods for identifying such selective anxiolytic therapeutic agents. The present invention also relates to methods for identifying a molecule that decreases binding of a benzodiazepine to the alpha1-GABAA receptor, but not substantially to the alpha2-GABAA receptor.
|
